Authors: Dokainish H et al., on behalf of the INTER-CHF Investigators
Summary: The INTER-CHF study prospectively enrolled 5813 consecutive ambulatory or hospitalised patients with HF (26% with HFPEF), including 1294 patients from Africa, 2661 from Asia, 1000 from the Middle-East and 858 from South America. Compared with patients from other regions, those from Africa, followed closely by those from Asia, were younger, had lower literacy levels and were less likely to have health or medication insurance or be receiving β-blockers, and were most likely to be NYHA class 4. South American patients were older, more literate, more likely to be insured and, along with those from the Middle East, more likely to be β-blocker recipients, and had the lowest proportion in NYHA class 4. The most common aetiology of HF was ischaemic heart disease among patients from all regions, with the exception of Africa where hypertensive heart disease was the most common aetiology.
Comment: This is the largest study to date comparing characteristics of HF patients across Africa, Asia, the Middle East and South America, with a specific focus on countries that have been under-represented in previous epidemiological studies. The young age, low literacy rates and low β-blocker prescription rates in Africa compared with other regions stand out. The particularly high rates of obesity and diabetes in the Middle East are also noteworthy. Furthermore, these data suggest epidemiological transition in Africa and Asia, with an increasing proportion of cases due to ischaemic heart disease compared with previous registries, which suggests that the full health and economic burden of HF is yet to be realised.
Reference: Int J Cardiol 2016; 204:133-41 Abstract Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy Authors: Hamshere S et al. Summary: The phase 2 REGENERATE-DCM trial randomised 60 patients with dilated cardiomyopathy with no secondary cause (LVEF ≤45%, NYHA class ≥2) to receive peripheral G-CSF, G-CSF plus intracoronary serum, G-CSF plus intracoronary bone marrowderived cells or placebo; G-CSF was administered for 5 days, and in the intracoronary arms this was followed by bone marrow-derived cells or serum on day 6. Participants in the peripheral G-CSF with intracoronary bone marrow-derived cell therapy arm had an increase in LVEF from 32.93% to 38.30% at 3 months (primary endpoint; p=0.0138), and this was maintained out to 1 year; there were also associated decreases in NYHA classification and NT-proBNP level and improvements in exercise capacity and quality of life. There were no significant changes in LVEF in the other groups.
Comment:
The majority of studies evaluating the safety and efficacy of cell therapy in the setting of LV dysfunction have been conducted in patients with ischaemic heart disease, with variable results reported. This is the first randomised, placebocontrolled study evaluating the combination of cytokines (G-CSF) and cell therapy (intracoronary autologous bone marrow-derived cells) in the setting of dilated cardiomyopathy. The study achieved its primary endpoint with a greater improvement in LVEF at 3 months, which was maintained for 1 year. This was accompanied by improvements in symptoms, exercise capacity and NT-proBNP reduction. Whilst these results are promising, they need to be confirmed in phase 3 studies powered for hard clinical outcomes.
Reference: Eur Heart J 2015; 36(44):3061-9 Abstract Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic Authors: Gundersen GH et al. Summary: This research included 62 outpatients with HF who underwent laboratory testing, history recording and clinical examination by two nurses with and without an ultrasound examination of the pleural cavities and IVC (inferior vena cava) in random order. Diuretic dosing differed between the groups for 31/119 consultations, and dose adjustments at follow-up were predicted by weight change and volume status assessed clinically with and without ultrasound (p<0.05), but changes in oedema, NT-proBNP level, creatinine level and symptoms were not. Adjusted analyses showed that only volume status based on ultrasound was a significant predictor of diuretic dose adjustment at first visit and follow-up.
Comment: This group have previously demonstrated high agreement between nurse-and cardiologistperformed ultrasound evaluation of the IVC and pleural cavities. In this small study, they demonstrated that the presence of a pleural effusion or a dilated IVC with reduced collapsibility was associated with higher 2-year mortality. Furthermore, this led to changes in management with nurse-performed, point-of-care ultrasound estimation of volume status being a better predictor of diuretic dose adjustment than other clinical measures (including change in BNP levels). This implies that the treating clinicians placed more weight on the ultrasound findings. Future studies will need to determine whether this leads to better health outcomes. † In patients with heart failure and left ventricular impairment within 3-14 days of acute myocardial infarction, in combination with standard therapy.
In post-MI heart failure protection comes as standard Summary: This research conducted in ten men and three women with continuous-flow LVADs sought to determine if restoring pulsatile flow via pump speed modulation would reduce muscle sympathetic nerve activity through the arterial baroreceptor reflex. Steady-state responses of beat-to-beat BP, carotid ultrasonography at the level of the arterial baroreceptors and muscle sympathetic nerve activity were recorded for stepped reductions in pump speed from 10,480 to 8500 revolutions per minute. Compared with high pump speed, low speed was associated with a significantly higher pulse pressure (26 vs. 17mm Hg [p<0.01]), significantly increased carotid artery distension and carotid arterial wall tension and decreased muscle sympathetic nerve activity (33 vs. 41 bursts per minute [p<0.01]), despite a reduction in mean arterial pressure; muscle sympathetic nerve activity was inversely related to pulse pressure (p=0.037).
Comment: This intriguing 'back-to-the-future' study utilised a cohort of patients with Heartmate II continuous axial-flow LVADs to confirm observations made in physiological experiments conducted in animals over two decades ago. The authors have previously reported that muscle sympathetic nerve activity is much higher in patients with continuous-flow LVADs compared with older generation pulsatile LVADs. By altering pump speed, they were able to induce pulsatile arterial flow, which resulted in a reduction in muscle sympathetic nerve activity, which the authors suggest is due to arterial baroreceptor-mediated inhibition of sympathetic outflow. Future studies will need to determine whether these findings are specific for axial-flow LVADs and the effect of longer term changes in pump speed on sympathetic outflow (perhaps estimated using total body noradrenaline [norepinephrine] spillover) and clinical outcomes.
Reference: Circulation 2015;132(24):2316-22 Abstract
Fully magnetically levitated left ventricular assist system for treating advanced HF Authors: Netuka I et al. Summary: The performance and safety of the HeartMate III LVAD was reported for 50 adults with EF ≤25%, cardiac index ≤2.2 L/min/m 2 without inotropes or inotrope-dependent on optimal medical management, or listed for transplant; indications for LVAD support were bridge to transplantation in 54% or destination therapy in 46%. Six-month outcomes included continued LVAD support in 88% of patients, transplantation in 4% and death in 8%, giving a 6-month survival rate of 92%, which exceeded the performance goal of 88%. Compared with the Seattle Heart Failure Model, mortality risk was reduced by 66% with the HeartMate III LVAD (p=0.0093), and improvements were also seen for NYHA classifications, 6-minute walk tests and quality of life scores. Reoperation for bleeding occurred in 14% of patients, driveline infection in 10%, gastrointestinal bleeding in 8% and debilitating stroke in 8%; there were no pump exchanges, malfunctions or thromboses or haemolytic events.
Comment: This multicentre, international study describes the first-in-man experience with the HeartMate III continuous, centrifugal-flow LVAD, which utilises a magnetically levitated rotor with large blood-flow paths to minimise shear stress and enhance haemocompatibility. The authors met their primary endpoint with a 92% 6-month survival, and a favourable adverse event rate, including a relatively low rate of major bleeding. In addition, the HeartMate III rotor speed is varied every 2 seconds to generate pulsatile flow; however, whether this results in a decrease in muscle sympathetic nerve activity (as reported in the previous paper by Cornwell et al. with an axial-flow LVAD) was not addressed. Meanwhile, there is an ongoing RCT (MOMENTUM 3) comparing the HeartMate II and HeartMate III LVADs.
Reference: J Am Coll Cardiol 2015;66(23):2579-89 Abstract
Which heart failure patients profit from natriuretic peptide guided therapy?
Authors: Brunner-La Rocca H-P et al. Summary: This was a meta-analysis of data from 1731 patients with HFREF versus 301 with HFPEF from eight randomised NT-proBNP guidance trials. Compared with symptom-guided therapy, NT-proBNP-guided therapy was associated with lower mortality risk and fewer HF admissions in patients with HFREF (respective hazard ratios 0.78 [95% CI 0.62-0.97] and 0.80 [0.67-0.97]), but not in patients with ] and 1.01 [0.67-1.53]; p<0.02 for interactions). An interaction was seen between age and treatment strategy independent of EF for mortality (p=0.02) but not HF admission (p=0.54), with the age-mortality interaction explained by the interaction of treatment strategy allocation with comorbidities. Among comorbidities, the strongest interaction for treatment allocation was seen for renal failure (i.e. increased risk of NT-proBNP-guided therapy if present) in patients with HFPEF (p<0.01), whereas in patients with HFREF, the strongest interaction was seen for the presence of ≥2 comorbidities (i.e. NT-proBNP-guided therapy beneficial only if ≤1 of chronic obstructive pulmonary disease, diabetes, cardiovascular insult or peripheral vascular disease was present; p<0.01). In patients with HFPEF without hypertension, NT-proBNP-guided therapy was harmful (p=0.02).
Comment:
The current patient data and other aggregate meta-analyses of RCTs have previously reported a mortality benefit and reduced HF hospitalisation in HF patients whose treatment was adjusted according to NT-proBNP levels. The current analysis seeks to clarify which patients are more likely to benefit. The benefit was mainly seen in HFREF, with no benefit in HFPEF. No survival benefit was seen in HFREF patients with ≥2 of four specific comorbidities (chronic obstructive pulmonary disease, diabetes, cerebrovascular accident/transient ischaemic attack or peripheral vascular disease), which largely explained why there was no mortality reduction in the elderly. Whilst this should be regarded as hypothesis-generating, the findings are biologically plausible given that the HFREF patients enrolled in the RCTs that informed our treatment guidelines were generally younger with fewer comorbidities than the real-world HF population.
Reference: Eur J Heart Fail 2015; 17(12) :1252-61 Abstract Differential impact of body position on the severity of disordered breathing in heart failure patients with obstructive vs. central sleep apnoea Authors: Pinna GD et al. Summary: These researchers assessed and compared sleep position on sleep apnoea severity in patients with moderate-to-severe HF and systolic dysfunction who also had OSA (n=29) or CSA (n= 91). Compared with the supine position, the lateral (right and left side combined) position was associated with a marked decrease in median AHI (apnoea-hypopnoea index) in participants with OSA and CSA (10.4 vs. 50.3 and 19.3 vs. 47.4 events per hour, respectively), with the decrease significantly greater in participants with OSA (p=0.027); similar reductions were seen in oxygen desaturation and the apnoea ratio (p<0.0001). Positional sleep apnoea (>50% AHI reduction between the supine and lateral positions) was more common among participants with OSA than CSA (76% vs. 53% [p=0.028]).
Comment: This study reports that a high proportion of both OSA (76%) and CSA (53%) are positional (based upon having a >50% reduction in AHI by sleeping in the lateral compared with the supine position) in a cohort of consecutive chronic HFREF patients. Whilst this finding is not unique for HF given the results of SERVE-HF (admittedly in a HFREF cohort with predominant CSA), it would seem reasonable to trial positional approaches (i.e. avoiding the supine sleeping position) in such patients.
